10 Jul 2018 11:00
10 July 2018
Evgen Pharma plc
("Evgen" or "the Company")
Grant of share options, issue of equity and total voting rights
Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions announces that Sally Ross, the Company's Clinical Development Officer, has been granted nil cost options over a total of 368,304 ordinary shares in the Company. The options are exercisable, subject to the option vesting, for a period of up to ten years from the date of grant under the Evgen Pharma plc Long Term Incentive Plan ("LTIP").
The number of nil cost options awarded has been calculated by reference to the three month average share price to 3 July 2018. These nil cost options are subject to the rules of the LTIP and will vest based on share price performance between the date of grant and the third anniversary of grant.
Issue of Equity
In addition, the Company announces that it has received a notice to exercise options over 80,000 ordinary shares in the Company. The options were granted under an individual option agreement and have an exercise price of 7.3 pence per share. Accordingly, the Company has issued and allotted 80,000 new ordinary shares of 0.25 pence each ("New Ordinary Shares"). The New Ordinary Shares rank pari passu with the Company's existing issued ordinary shares. Application has been made to admit the New Ordinary Shares to trading on AIM and dealings in these shares are expected to commence at 8.00 a.m. on 12 July 2018.
Total Voting Rights
There are no shares held in treasury, therefore following the admission of the New Ordinary Shares the total number of voting rights in the Company will be 93,356,858. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest under the Disclosure and Transparency Rules.
Enquiries:
Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO | +44 (0) 01625 466591 | |
Buchanan Mark Court, Sophie Cowles, Stephanie Watson | +44 (0) 20 7466 5000 | |
Northland Capital Partners Limited Matthew Johnson, Tom Price (Corporate Finance) John Howes, Rob Rees (Corporate Broking) | +44 (0) 20 3861 6625 | |
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/
Details of the person discharging managerial responsibilities/person closely associated | ||
Name | Sally Ross | |
Reason for the notification | ||
Position/status | Clinical Development Officer | |
Initial notification /Amendment | Initial Notification | |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
Name | Evgen Pharma Plc | |
Legal Entity Identifier | 213800NO3E6TSTQO8K20
| |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
Description of the financial instrument, type of instrument
Identification code | Options over ordinary shares of 0.25 pence each GB00BSWYN304
| |
Nature of the transaction | Grant of options | |
Currency | GBP | |
Price(s) and volume(s) | Price(s) | Volume(s) |
nil | 368,304 | |
Aggregated information - Aggregated volume - Price - Aggregated total |
| |
Date of the transaction | 7 July 2018 | |
Place of the transaction | Off market | |